Clinical Trial Update: Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects [Phase 3]

View source ↗

Summary

Phase 3 immunogenicity and safety study of GSK HPV vaccine in healthy female subjects has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Papillomavirus Infections

Drugs mentioned

• HPV vaccine (GSK Biologicals' HPV 580299 vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 3 | Status: COMPLETED | Results posted: 2012-06-27